Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eldecalcitol vs alfacalcidol in primary osteoporosis (Chinese patients)
jRCT2080222852Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of eldecalcitol in involutional osteoporosis (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change in lumbar spine bone mineral density at 12 months. Started May 2015; status: completed.
02
Drugs
eldecalcitol
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCT2080222852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222852.